Otsuka (OTCMKTS:OTSKY) Stock Passes Below Fifty Day Moving Average – Should You Sell?

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY)’s stock price crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $34.98 and traded as low as $32.50. Otsuka shares last traded at $32.52, with a volume of 50,295 shares.

Analysts Set New Price Targets

OTSKY has been the subject of several analyst reports. The Goldman Sachs Group cut Otsuka from a “strong-buy” rating to a “strong sell” rating in a report on Friday, February 27th. Zacks Research raised Otsuka from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 31st. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Otsuka has a consensus rating of “Hold”.

Otsuka Price Performance

The stock has a market capitalization of $34.93 billion and a price-to-earnings ratio of 13.72. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.67 and a current ratio of 2.17. The company has a fifty day simple moving average of $34.98 and a two-hundred day simple moving average of $32.09.

Otsuka (OTCMKTS:OTSKY) last announced its quarterly earnings data on Tuesday, April 28th. The company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.16. Otsuka had a return on equity of 12.33% and a net margin of 15.01%.The firm had revenue of $3.96 billion during the quarter, compared to analysts’ expectations of $3.78 billion. Otsuka has set its FY 2026 guidance at 1.610-1.610 EPS. As a group, equities research analysts expect that Otsuka Holdings Co., Ltd. – Unsponsored ADR will post 1.99 earnings per share for the current fiscal year.

About Otsuka

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.